These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 26971992)
1. Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. Roviello G; Sigala S; Danesi R; Re MD; Bonetta A; Cappelletti MR; Zanotti L; Bottini A; Generali D Crit Rev Oncol Hematol; 2016 May; 101():12-20. PubMed ID: 26971992 [TBL] [Abstract][Full Text] [Related]
2. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R; Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659 [TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ; Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048 [TBL] [Abstract][Full Text] [Related]
6. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; De Cobelli O; Nolè F Eur J Cancer; 2015 Sep; 51(14):1970-7. PubMed ID: 26169016 [TBL] [Abstract][Full Text] [Related]
7. Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis. Roviello G; Corona SP; Generali D Med Oncol; 2017 Aug; 34(10):166. PubMed ID: 28852974 [TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE; Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341 [TBL] [Abstract][Full Text] [Related]
9. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882 [TBL] [Abstract][Full Text] [Related]
10. CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials. Cao Q; Bai P; Shi D; Liao J; Shi H; Xing Y; Chen K; Zhang X J Cancer Res Ther; 2020 Sep; 16(5):990-1001. PubMed ID: 33004739 [TBL] [Abstract][Full Text] [Related]
11. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059 [TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients. Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185 [TBL] [Abstract][Full Text] [Related]
13. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer]. Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676 [TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374 [TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. Conteduca V; Caffo O; Derosa L; Veccia A; Petracci E; Chiuri VE; Santoni M; Santini D; Fratino L; Maines F; Testoni S; De Giorgi U Prostate; 2015 Sep; 75(12):1329-38. PubMed ID: 25982919 [TBL] [Abstract][Full Text] [Related]
17. [Abiraterone acetate(ZYTIGA®)-development and literature review]. Nishimura Y; Mukai H; Suzukawa K; Oyama R Gan To Kagaku Ryoho; 2014 Jul; 41(7):811-6. PubMed ID: 25131865 [TBL] [Abstract][Full Text] [Related]
18. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562 [TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642 [TBL] [Abstract][Full Text] [Related]
20. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. Roviello G; Sigala S; Sandhu S; Bonetta A; Cappelletti MR; Zanotti L; Bottini A; Sternberg CN; Fox SB; Generali D Eur J Cancer; 2016 Jul; 61():111-21. PubMed ID: 27162152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]